The Patent Finder

Metro International Biotech, LLC

24 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 27, 2027
  • 1 fee due Apr 17, 2027
    The maintenance fee for Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use (US 11,787,830) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 2 fees due Jul 23, 2027
  • 1 fee due Aug 4, 2027
    The maintenance fee for Nicotinamide Mononucleotide Derivatives and Their Uses (US 10,548,913) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 2 fees due Sep 26 to 30, 2027 · next Sep 26
  • 3 fees due Oct 9 to 16, 2027 · next Oct 9

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,603,334Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
In force
 · USPTO record
In forceUSPTO record
US 11,389,469Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
In force
 · USPTO record
In forceUSPTO record
US 9,855,289Nicotinamide Mononucleotide Derivatives and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 9,919,003Nicotinamide Mononucleotide Derivatives and Their Uses
In force
 · High confidence
In forceHigh confidence
US 10,548,913Nicotinamide Mononucleotide Derivatives and Their Uses
In force
 · Low confidence
In forceLow confidence
US 11,464,796Nicotinamide Mononucleotide Derivatives and Their Uses
In force
 · Low confidence
In forceLow confidence
US 11,878,027Nicotinamide Mononucleotide Derivatives and Their Uses
In force
 · Low confidence
In forceLow confidence
US 12,485,135Nicotinamide Mononucleotide Derivatives and Their Uses
In force
 · Low confidence
In forceLow confidence
US 10,233,208Crystal Forms of Beta-Nicotinamide Mononucleotide
In force
 · High confidence
In forceHigh confidence
US 10,392,415CRYSTAL FORMS OF b-NICOTINAMIDE MONONUCLEOTIDE
In force
 · High confidence
In forceHigh confidence
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited